Value-Based Medicine (VBM) for Lung Cancer

Summary

This is a prospective observational monocentric trial. The primary endpoint is the validation of predictive models. These predictive models will be used to develop a personalized clinical-functional risk profile for estimating in advance, prior to surgery, the probability for a patient to experience surgical complications, pain, fatigue, dyspnea, as well as issues related to physical function, role, social, and emotional well-being, up to 12 months post-discharge.

Eligibility

Inclusion Criteria:

* Patients aged ≥ 18 years
* Patients with diagnosis of non-small cell lung carcinoma
* Only patients eligible for surgical lung resection (lobectomy/typical and atypical segmentectomy) with or without neo-adjuvant and adjuvant therapy
* Diagnosis of primary non-small cell lung cancer
* Signed Informed Consent
* Patients must be available for follow-up

Exclusion Criteria:

* Patients with benign lesion
* Patients with recurrence who have already undergone lung surgery
* Conditions/pathologies that prevent the ability to give consent

Conditions2

Browse More Trials